Adaptive Biotechnologies to Report Second Quarter of 2022 Financial Results on August 3, 2022

Rhea-AI Summary

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) is set to report its second quarter 2022 financial results after the market closes on August 3, 2022. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET. The company focuses on leveraging the adaptive immune system to develop diagnostic and therapeutic products for various diseases, including cancer and autoimmune conditions. The call will be accessible to registered participants, and a replay will be available on the company’s website within 24 hours.

Positive

• Upcoming financial report for Q2 2022 may provide insights into growth and performance.
• Adaptive Biotechnologies has three commercial products and a solid clinical pipeline.

Negative

• None.

SEATTLE, July 08, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2022 after market close on Wednesday, August 3, 2022. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

To attend the conference call or webcast, participants should register online. Participants are requested to register a day in advance or at a minimum 15 minutes before the start of the call. The webcast will be archived and available for replay within 24 hours after the event on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in our Immune Medicine and Minimal Residual Disease (MRD) businesses. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. For more information, please visit adaptivebiotech.com and follow us on www.twitter.com/adaptivebiotech. 

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com 

ADAPTIVE MEDIA
Laura Cooper
206-693-2042
media@adaptivebiotech.com 

FAQ

When will Adaptive Biotechnologies report its Q2 2022 earnings?

Adaptive Biotechnologies is scheduled to report its Q2 2022 earnings after market close on August 3, 2022.

What time is the conference call for Adaptive Biotechnologies Q2 2022 results?

The conference call for Q2 2022 results will take place at 1:30 p.m. PT / 4:30 p.m. ET on August 3, 2022.

How can I access the Q2 2022 earnings call for ADPT?

Participants can register online to attend the Q2 2022 earnings call for Adaptive Biotechnologies.

What are the key focus areas of Adaptive Biotechnologies?

Adaptive Biotechnologies focuses on utilizing the adaptive immune system to develop products for diagnosing and treating diseases such as cancer and autoimmune conditions.